This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Unituxin

United Therapeutics Corporation

Drug Names(s): Chimeric monoclonal antibody 14.18, Ch14.18 MAb

Description: Ch14.18 is a chimeric human-murine monoclonal antibody against the tumor-associated disialoganglioside GD2. GD2 expression is normally restricted to neurons, skin melanocytes, and peripheral sensory nerve fibers. It is also highly expressed in neuroblastomas.

Ch14.18 is designed to stimulate antibody-dependent cell-mediated cytotoxicity and may be developed in combination with granulocyte-macrophage colony-simulating factor (CM-CSF) or interleukin 2 to augment its activity.

Deal Structure: In July 2010, United Therapeutics entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the late-stage development and regulatory agency submissions of Chimeric Monoclonal Antibody 14.18 (Ch14.18).


Unituxin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug